Clonidine Does Not Potentiate the Antipsychotic Effects of Neuroleptics in Chronically Ill Patients
Tóm tắt
Clonidine is a centrally acting antihypertensive and has been prescribed widely for more than 20 years. Because it decreases central norepinephrine activity, clonidine has been investigated as an antipsychotic. In most of the preliminary studies, clonidine was tested as the sole antipsychotic agent. We performed a double-blind, placebo-controlled, crossover study to compare a placebo plus a neuroleptic to clonidine plus a neuroleptic in a group of 16 chronically psychotic patients. Of these 16, 3 dropped out secondary to side effects of the clonidine and 1 withdrew from the study. The clonidine dosage varied from 0.2 to 0.6 mg per day. The concurrent neuroleptic (one of the following: haloperidol, thiothixene, thioridazine, mesoridazine, or fluphenazine) averaged 34 mg per day of haloperidol equivalents. Symptoms were monitored using the Psychiatric Symptoms Assessment Scale. The data provided evidence that a clonidine/neuroleptic combination was not more effective than a neuroleptic alone in this group of patients. These data suggest that the central antino-repinephrine activity of a neuroleptic is not potentiated further by clonidine.
Tài liệu tham khảo
Lowenstein J: Drugs five years later: Clonidine. Ann Intern Med 1980; 92:74–77
Langer SZ: Sixth Gaddum Lecture: National Institute for Medical Research, Mill Hill, Jan 1977. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol 1977; 60:481–497
Medgett IC, McCulloch MW, Rand MJ: Partial agonist of clonidinc on prejunctional and postjunctional alpha adrenoceptor. Naunyn-Schmiedeberg Arch Pharmacol 1978; 304:215–221
Ciofalo JR: Effect of some antiarrhythmics on [3H]clonidine binding to alpha 2 adrenergic receptors. Eur J Pharmacol 1980; 65:309–312
Goodwin FK, Post RM: In: Freedman D, ed. The Biology of the Major Psychosis: A Comparative Analysis. New York: Raven Press; 19:229–332
Farley JJ, Price KS, McCullogh E, Deck JHN, Hordynski W, Hornykiewicz O: Norepinephrine in chronic paranoid schizophrenia: Above normal levels in limbic forebrain. Science 1978; 200:456–458
Gomes UCR, Stanley BC, Potgieter L, Roux JT: Noradrenergic overactivity in chronic schizophrenia: Evidence based on cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations. Br J Psychiatry 1980; 137:346–351
Lake CR, Sternberg DE, van Kammen DP, Ballenger JC, Ziegler MG, Post RM, Kopin IJ, Bunney WE: Schizophrenia: Elevated cerebrospinal fluid norepinephrine. Science 1980; 207:331–333
Hornykiewicz O: Brain catecholamines in schizophrenia: A good case for noradrenaline. Nature 1982; 299:484–486
Swann AC, Secunda S, Davis JM, Robins E, Hanin I, Koslow SH, Maas JW: CSF monoamine metabolites in mania. Am J Psychiatry 1983; 140:396–400
Redmond DE Jr, Katz MM, Maas JW, Swann A, Casper R, Davis JM: Cerbrospinal fluid amine metabolites: Relationship with behavioral measurements in depressed, manic, and healthy control subjects. Arch Gen Psychiatry 1986; 43:938–947
Simpson GM, Kunz-Bartholini E, Watts TPS: A preliminary evaluation of the sedative effects of Catapres, a new antihypertensive agent, in chronic schizophrenic patients. J Clin Pharmacol 1967; 7:221–225
Sugarman AA: A pilot study of ST-155 (Catapres) in chronic schizophrenics. J Clin Pharmacol 1967; 7:226–228
van Kammen DP, Peters JL, van Kammen WB, et al.: Clonidine treatment of schizophrenics: Can we predict treatment response? Psychiatry Res 1989; 27:297–311
Angrist B, Smith M, Adler L, et al.: Preliminary studies of clonidine in psychotic patients. J Neural Transm 1988; 71:115–121
Freedman R, Kirch D, Bell L, et al.: Clonidine treatment of schizophrenia: Double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatr Scand 1982; 65:35–45
El-Mallakh RS: The use of clonidine in psychiatry. Res Staff Phys 1992; 38:29–33
Hardy MC, Lecrubier Y, Widlöcher D: Efficacy of clonidine in 24 patients with acute mania. Am J Psychiatry 1986; 143:1450–1453
Glannini AJ, Extein I, Gold MS, et al.: Clonidine in mania. Drug Dev Res 1983; 3:101–103
American Psychiatric Association: Diagnostic and Statistical Manual III, Revised. Washington, DC: American Psychiatric Press, 1987
American Psychiatric Association: Structured Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Press; 1990
Bigelow L, Bryan D: The Psychiatric Symptom Assessment Scale (PSAS). Psychopharm Bull 1989; 25:168–179
Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1963; 10:799–812
Cohen J: Statistical Power Analysis for Behavior Science, 2nd ed. Lawrence Erlbaum Associates; Hillsdale, NJ: 1988
Karson CN, Kleinman JE, Wyatt RT: Biochemical concepts of schizophrenia. In: Millon T, Klerman GL (eds). Contemporary Directions in Psychopathology. New York: Guilford Press; 1986
Kafka MS, van Kammen DP: α-Adrenergic receptor function in schizophrenia. Arch Gen Psychiatry 1983; 40:264–270
Farley IJ, Sharnak KS, Hornykiewicz O: Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased dopamine receptor sensitivity. In: Pepen G, et al. (eds). Receptors for Neurotransmitters and Peptide Hormones. New York: Raven Press, 1980
Kaplan HI, Sadock BJ: Comprehensive Textbook of Psychiatry/V. Baltimore, MD: Williams & Wilkins; 1985; 1591–1626
Kleinman JE, Bridge TP, Karoum F, Speciale S, Staub R, Zalcman S, Gillin JC, Wyatt RJ: Catecholamines and metabolites in the brains of psychotics and normals: Post-mortem studies. In: Usdin E, Kopin IJ, Barchas JD (eds). Catecholamines: Basic and Clinical Frontiers. Elmsford, NY: Pergamon Press; 1979:1845–1847
Charney DS, Bremner D, Redmund DE: Noradrenergic neural substrates for anxiety and fear. In: Bloom FE, Kupfer DJ (ed). Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1955:387–395
Morpurgo C: Aggressive behavior induced by large doses of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST-155) in mice. Eur J Pharmacol 1968; 3:374–377